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Abstract 
With the increasing prevalence of end stage renal disease there is a growing need for 
hemodialysis. Arteriovenous fistulae (AVF) are the preferred type of vascular access for 
hemodialysis but maturation and failure continue to present significant barriers to successful 
fistula use. AVF maturation integrates outward remodeling with vessel wall thickening in 
response to drastic hemodynamic changes, in the setting of uremia, systemic inflammation, 
oxidative stress and preexistent vascular pathology. AVF can fail due to both failure to 
mature adequately to support hemodialysis, as well as development of neointimal hyperplasia 
(NIH) that narrows the AVF lumen, typically near the fistula anastomosis. Failure due to NIH 
involves vascular cell activation and migration and extracellular matrix remodeling with 
complex interactions of growth factors, adhesion molecules, inflammatory mediators, and 
chemokines, all of which result in maladaptive remodeling. 
Different strategies have been proposed to prevent and treat AVF failure, based on current 
understanding of the modes and pathology of access failure; these approaches range from 
appropriate patient selection and use of alternative surgical strategies for fistula creation, to 
the use of novel interventional techniques or drugs to treat failing fistulae.  Effective 
treatments to prevent or treat AVF failure requires a multidisciplinary approach involving 
nephrologists, vascular surgeons and interventional radiologists, allowing careful patient 
selection and the use of tailored systemic or localized interventions to improve 
patient-specific outcomes. This review provides contemporary information on the underlying 
mechanisms of AVF maturation and failure and discusses the broad spectrum of options that 
can be tailored for specific therapy. 
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Introduction 
 
1. The prevalence of ESRD is increasing 
Chronic kidney disease (CKD) is increasing in incidence worldwide, and with an 
estimated prevalence of 8%–16%, contributes significantly to the global burden of disease [1, 
2]. The global prevalence of diabetes in adults is 9.1% (415 million people) according to a 
report published in 2015 by the International Diabetes Federation, rising beyond 10.4% (642 
million people) by 2040 [3], largely due to the global increase in type 2 diabetes and obesity, 
especially in China, India and some developing countries in Africa [4-6]. This increase in the 
number of people developing diabetes has had a major impact on the development of diabetic 
kidney disease (DKD). DKD and an aging population have become the two challenges in 
managing end-stage renal disease (ESRD) worldwide. DKD is the leading cause of ESRD, 
accounting for approximately 50% of cases in the developed world. Although overall 
incidence rates for ESRD attributable to DKD have recently stabilized in the USA, these rates 
continue to rise in high-risk groups such as middle-aged African Americans, Native 
Americans, and Hispanics. The elderly population constitutes the fastest growing sector of 
the ESRD population and have unique needs by virtue of their high prevalence of comorbid 
conditions, slower progression of renal disease, and reduced survival; in the Medicare 
population alone, DKD-related expenditure among the elderly was nearly $25 billion in 2011 
[7, 8]. With the increasing prevalence of ESRD, there is a growing need for renal replacement 
therapies (RRT). 
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2. AVF is the preferred form of RRT but is far from optimal 
RRTs are the lifeline for ESRD patients. Modes of RRT include peritoneal dialysis 
(6.4%), renal transplant (29.3%), and hemodialysis (HD) (64.2%) [9, 10]. In 2010, 64.7% of 
patients in the United States with ESRD were treated with HD with either arteriovenous 
fistula (AVF), arteriovenous grafts (AVG), or tunneled and non-tunneled central venous 
catheters [11]. 
The National Kidney Foundation Kidney Disease Outcomes Quality Initiative 
(NKF-KDOQI) guidelines and the Fistula First Breakthrough Initiative prefer AVF as the 
optimal access for HD [12], as they have superior patency rates, fewer complications and 
lower health care costs [11, 13-15]. Additionally, a recent systematic review and 
meta-analysis on outcomes of vascular access for hemodialysis remains in support of 
autogenous access as the best approach when feasible: AVF were associated with the best 
patency and lowest infection and mortality outcomes, followed by AVG and catheters [16, 
17]. AVF have also been recommended in the pediatric population [18].  
However, AVF are not immediately available for use as an access for HD as they must 
mature, e.g. dilate and thicken. Unfortunately, AVF have a high rate of primary maturation 
failure with up to 60% not suitable for HD by 5 months after creation [19-22]. Furthermore, a 
recent systematic review and meta-analysis reported that the primary patency rates of AVF 
were 60% at 1 year and 51% at 2 years, with secondary patency rates of 71% at 1 year and 64% 
at 2 years, clearly suboptimal for a permanent treatment [23].  Although there are conflicting 
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results regarding sex influence on AVF failure, most studies demonstrated that women have 
prolonged maturation time and decreased patency rate [17, 24, 25]; early thrombosis was also 
associated more frequently with women [26]. Controversially, AVF may not be favored for 
HD access in older patients [27-29]. Olsha et al demonstrated that 88% of their patients who 
were older than 80 years had vasculature suitable for autogenous access construction, with 
patency and complications similar to those of their younger counterparts, with adequate 
preoperative planning and postoperative maintenance [29]. However, elderly patients with 
ESRD frequently have a high prevalence of comorbidities, short life expectancy, and poor 
reported quality of life that is associated with lack of AVF maturation and diminished 
primary and cumulative AVF patency [28]; in these patients AVG placement might be more 
beneficial [27, 28, 30]. 
 
3. Lack of well-established clinical criteria to define AVF maturation or failure 
AVF maturation is considered clinically successful if 6 weeks after surgery the fistula 
supports a flow of 600 mL/min, is located at a maximum of 6 mm from the skin surface and 
has a diameter of >6 mm [12], but this definition is difficult for clinical use. The North 
American Vascular Access Consortium definition may be more useful: a fistula is mature if it 
can be successfully used for dialysis with two-needle cannulation for two-thirds or more of 
all dialysis runs for 1 month and if it delivers the prescribed dialysis within the prescribed 
time frame [31]. 
Although there are some clinical criteria to define successful AVF maturation, the 
clinical definition of AVF failure is less clear, with frequent confusion between various types 
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and stages of failure. Based on previous criteria and recent multicenter research [12, 26, 31], 
we have defined the 3 types of AVF failure as: early thrombosis, failure to mature, and late 
failure (Table 1). 
Many variables contribute to successful AVF maturation or AVF failure: patient age, sex, 
presence of diabetes, obesity, vessel characteristics, surgical technique and surgeon 
experience, preoperative planning and mapping [32-34]. Successful access surgeons 
frequently adhere to the dictum that a successful AVF should be performed in the right 
patient at the right time in the right circumstances based upon comprehensive understanding 
of the mechanisms contributing to AVF maturation and AVF failure. The goal of this review 
paper is to give a basic understanding of the adaptive changes of AVF maturation as a 
framework to understand the mechanisms of AVF failure as well as subsequent treatments. 
 
Mechanisms contributing to AVF maturation and failure 
 
Mechanisms of AVF maturation 
 
1. AVF maturation integrates outward remodeling and wall thickening 
After AVF creation, the vein is exposed to a high flow, high shear stress, high pressure, 
and oxygen-rich arterial environment, leading to “maturation” of both the arterial inflow limb 
as well as venous outflow limb. Adaptation of the vein to the increased flow and shear stress 
of the arterial environment requires dilation by outward remodeling of the venous wall, 
(Poiseuille’s law), whereas increases in pressure and tensile stress result in wall thickening, 
(Laplace’s law). During this adaptive remodeling, hemodynamic changes are translated into 
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endothelial and adventitial signaling, inducing structural changes in cells and the extracellular 
matrix (ECM); inflammation, growth factors and cell adhesion molecules in all three layers 
of the venous wall are involved with the process inducing remodeling (Figure 1). 
1.1 Hemodynamic flow  
Blood flow in the cephalic vein is normally approximately 28 ± 14 ml/min [35]. 
Successful radial-cephalic AVF have flow rates averaging between 600-1000 ml/min with 
higher peak flows in the larger diameter brachial-cephalic AVF. Dixon et al. reported that 90% 
of forearm AVF have flows between 500-2000 ml/min, whereas 90% of upper arm AVF have 
flows between 500-3000 ml/min [36]. Shear stress in the cephalic limb of a brachial-cephalic 
fistula increases from preoperative venous magnitudes of 5-10 dyne/cm
2
 to 24.5 dyne/cm
2
 
after one week, which then normalizes to 10.4 dyne/cm
2
 over 3 months [37].  With these 
high magnitudes of flow in the AVF, the character of the flow may be disturbed, e.g. 
non-laminar and disordered, possibly even turbulent [38-41]. 
 
1.2 Outward remodeling and wall thickening  
AVF maturation is the product of both vessel wall outward remodeling and thickening 
and is thought to be an adaptive process to the increased pressure, shear stress, and oxygen 
tension from the arterial inflow that is no longer attenuated by resistive forces of the 
arterioles and the capillary bed. Different from vein grafts, AVF adapt mainly via outward 
dilation and wall thickening with less intimal thickening [42]. Schwartz et al. confirmed this 
behavior using a rabbit model, showing that AVF are exposed to higher flow than vein grafts 
(AVF: 82 ± 17 ml/min; vein grafts: 16 ± 4 ml/min) as well as increased shear stress (AVF: 71 
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± 50 dyne/cm
2
; VG: 0.96 ± 0.38 dyne/cm
2
). AVF showed increased dilation (AVF: 194%; VG: 
no change), whereas vein grafts were exposed to higher pressure (VG: 62 ± 3 mmHg; AVF: 6 
± 2 mmHg) and had increased myointimal area (VG: 4.72 ± 0.83 mm
2
; AVF: 1.9 ± 0.55 
mm
2
)[43]. 
Outward remodeling is thought to be mediated by the venous endothelium and adventitia 
that sense hemodynamic forces and integrates these forces to allow successful adaption 
without loss of luminal area and vessel patency [21, 24, 44, 45]. Venous diameter expansion 
is a critical element of outward remodeling and predicts clinical success for both AVF and 
vein grafts [46-48]. Several studies examining venous dilation in AVF reported mean 
diameter increases from 2.3-3.2 to 5.8-6.6 mm by 3 months after fistula creation. These 
values reflect a 45%-86% increase within the first month and an increase of up to 179% after 
3 months, corresponding to an average cross-sectional area of approximately 10-12 mm
2
, to 
normalize the shear stress [49, 50].  
Wall thickening is the adaptation of the vessel wall to increased pressure. This process 
involves expansion of all the vessel layers via both ECM deposition and cell proliferation and 
migration [44, 45, 51]. Several types of cells are involved in wall thickening, including 
smooth muscle cells, adventitial fibroblasts, and bone marrow derived progenitor cells [45, 
52-54].  The adventitial myofibroblast is critical during venous adaptation to arterial flow 
and helps maintain venous wall integrity and hemostasis after surgical creation of the AVF 
[45]. Myofibroblast precursors residing in the venous adventitia sense the abrupt mechanical 
forces produced by arterial flow to rapidly adjust their genomic expression program to help 
increase vascular resistance. This adaptive response includes the formation of bundles of 
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contractile microfilaments and extensive cell-to-matrix attachment sites as well as the 
secretion of MMPs, collagen, and ECM proteins that strengthen the fistula wall [45, 55]. 
Targeting the adventitia to treat NIH is a newer strategy to prevent AVF venous stenosis [56]. 
 
1.3 Endothelial Signaling 
Molecular signaling within the maturing AVF is of vital importance to understand and 
control the normal adaptive response of fistula maturation and the abnormal maladaptive 
response of fistula failure. The release of chemotactic and inflammatory mediators from the 
endothelium during surgical manipulation and hemodynamic variation are important during 
the initial phase of adaptation. Directly after AVF creation, high magnitudes of arterial flow 
result both in passive vascular distention and nitric oxide (NO) synthesis by endothelial cells 
with subsequent vascular smooth muscle cell (VSMC) relaxation, resulting in acute 
vasodilation [57-59]. NO is produced by endothelial nitric oxide synthase (eNOS), and is a 
potent vasodilator and signaling molecule with anti-inflammatory and anti-platelet properties 
[51, 59, 60]. eNOS may contribute to adaptive vein wall remodeling both through its 
anti-inflammatory and anti-thrombotic properties as well as through its anti-proliferative 
properties. Both eNOS and inducible nitric oxide synthase (iNOS) are upregulated in the 
AVF and may mediate adaptation; inhibition of eNOS results in increased MCP-1 and IL-8, 
leading to NIH [54, 61].  Endothelin-1 (ET-1) is an inflammatory mediator of 
vasoconstriction and endothelial proliferation. ET-1 expression is upregulated in the venous 
wall and within areas of NIH in AVF as well as in the plasma of patients with chronic renal 
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failure and hemodialysis; ET-1 may mediate wall thickening in response to localized 
hemodynamic forces [62-64]. 
 
1.4 Matrix remodeling 
Venous adaptation of AVF also depends on coordinated synthesis, secretion, and 
degradation of ECM [42]. The matrix metalloproteinase (MMP) family regulates ECM 
remodeling and allows cell migration through degradation of collagen and elastin.  MMP 
activity is stimulated by a variety of factors present during vein graft adaptation including 
flow, stretch, mechanical injury, inflammation, and oxidative stress [65-69]. In AVF, MMP-2 
and MMP-9 expression are upregulated, and a high serum ratio of MMP-2 to TIMP predicts 
AVF maturation [61, 65, 66, 68]. 
During AVF venous limb maturation, the process of ECM expression, synthesis, 
secretion, and deposition occurs in distinct temporal phases (Figure 2) [70]. Initial ECM 
degradation occurs early after AVF creation, coincident with early increased expression of 
MMP and tissue inhibitor of metalloproteinase 1 (TIMP-1). By day 7 there is increased 
expression of many collagen subunits as well as changing patterns of MMP expression. By 
day 21, a later phase is characterized by reduced MMP expression and increased expression 
of larger structural and non-collagenous matrix proteins. 
Matrix degradation is regulated by MMP whereas matrix deposition is regulated by 
transforming growth factor-β (TGF-β); TGF-β is produced by a variety of cell types present 
in the venous wall, including endothelial, smooth muscle, and inflammatory cells, potentially 
contributing significantly to intimal and medial thickening [63, 71, 72]. TGF-β is upregulated 
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at both early and later time points after AVF formation, depending on the model, and this 
expression correlates with ECM accumulation [61, 71, 73, 74]. 
 
1.5 Adventitia and perivascular cells 
With growing recognition of the importance of the adventitia and perivascular cells to 
vascular remodeling, the role of adventitial fibroblasts has gained attention. Recent data 
suggests that NIH consists of smooth muscle alpha-actin-positive, vimentin-positive and 
desmin-negative myofibroblasts that have probably migrated from the adventitial layer [52, 
75]. AVF failure is associated with an increased adventitial fibrosis, myofibroblast activation 
and capillary rarefaction [76].  
Molecular signals originating from the adventitia and perivascular cells play essential 
roles in regulation of vascular development, physiology, vascular wall remodeling, immune 
surveillance, and vascular disease. The adventitia contains many different interacting cell 
types including fibroblasts, microvascular endothelium, nerves, resident macrophages, T cells, 
B cells, mast cells, and dendritic cells; the adventitia is also the home to resident vascular 
progenitor cells [77]. Perivascular adipose tissue (PVAT) plays multiple roles in vascular 
physiology and remodeling including production of vasorelaxing and anticontractile factors 
[78, 79]. One important component of this adipose tissue–derived anticontractile activity is 
adiponectin. Adiponectin is an adipocyte-derived 244 amino acid long peptide hormone that 
regulates metabolic processes such as fatty acid oxidation, and also mediates vasorelaxation. 
Adiponectin receptors on VSMC activate calcium-sensitive potassium channels (BKca) 
leading to stimulation of eNOS activity and production of NO [80]. A similar pathway exists 
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in endothelial cells. Together, the production of NO from endothelial cells and SMC mediates 
the anticontractile effects of PVAT-derived adiponectin [79].  
 
Mechanisms of AVF failure 
  
1. Early thrombosis 
Blood, flow and the vessel wall, components of Virchow’s triad, are traditionally 
considered to be the three critical components of thrombosis [81].  Patients with ESRD 
show both a bleeding risk and an increased risk of thrombosis. The bleeding episodes involve 
platelet dysfunction, impaired platelet–vessel wall interactions and anemia [82-84], in 
addition to the use of anticoagulants during hemodialysis.  Several clinical trials have also 
shown increased risk of both spontaneous venous and arterial thrombosis along the entire 
spectrum of CKD, beginning from CKD stage 2 to stage 5 patients [85-87].  
ESRD is characterized by a number of metabolic abnormalities that alter the balance of 
pro- and anti-thrombotic factors that affect both thrombosis and hemostasis [88]. This is 
likely to be an important contributor to the increased risk of thrombosis in patients with 
ESRD. Several pro-thrombotic hemostatic mediators are elevated in CKD patients, including 
fibrinogen, which directly contributes to a hypercoagulable state [89], soluble 
thrombomodulin [90], soluble tissue factor (TF), thrombin-anti-thrombin (TAT) [91], von 
Willebrand factor (vWF) [91], factor VIII and C-reactive protein (CRP) [91, 92]. The 
generalized inflammatory state, endothelial dysfunction and possibly poor clearance of some 
of the thrombotic mediators may account for this metabolic derangement [89]. CKD and 
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ESRD patients have a disrupted endothelial glycocalyx, which also contributes to the 
increased risk of thrombosis [93, 94]. The endothelial cells of uremic patients express 
elevated levels of tissue factor, a crucial procoagulant activating the extrinsic coagulation 
cascade [95, 96]. Uremic endothelial cells also release small extracellular vesicles, called 
microparticles, loaded with TF to augment thrombosis.[96-98]. 
In addition, hypercoagulable states also predispose to an increased risk of early 
thrombosis. Factor V Leiden polymorphism has been inconsistently implicated [99, 100]. 
High levels of phospholipid antibodies, probably due to the uremic state and high levels of 
low density lipoprotein have similarly shown an association [101, 102]. 
In the setting of the pro-thrombotic state of ESRD, lack of surgical experience and 
insufficient preoperative vessel mapping can result in early thrombosis. A study from the 
Hemodialysis Fistula Maturation Study group showed that factors that contribute to early 
thrombosis include: female sex, use of forearm AVF, smaller arterial size, draining vein 
diameter of 2 to 3 mm, and protamine use [26]. Patient selection, sufficient preoperative 
mapping and an appropriately experienced surgical team are important to prevent early 
thrombosis. 
 
2. AVF failure to mature 
Effects of Hemodynamic Flow and Shear Stress 
In response to the hemodynamic changes after AVF creation, an AVF will undergo 
adaptive remodeling with outward remodeling and increased wall thickness. But in the setting 
of pre-existent vasculopathy and systemic abnormalities, an AVF will fail to mature either 
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because of aggressive NIH or impaired outward remodeling, or both. Although most research 
on the pathophysiology of AVF maturation failure focuses on NIH, the role of vascular 
outward remodeling should be also highlighted [103]. 
The increased hemodynamics of arterial flow that increases vessel wall shear stress 
(WSS) is likely to be a critical event after AVF creation that promotes AVF adaptation 
[104-106].  In a patient-specific side-to-end fistula, image-based computational fluid 
dynamics studies showed laminar flow within the arterial limbs and a complex 
multidirectional and reciprocating flow field on the inner side of the swing segment in the 
proximal venous limb [106]. NIH is predisposed to occur in the inner wall of the venous 
segment near the anastomosis, and has a strong inverse correlation with magnitudes of shear 
stress, but is also related to flow patterns [107].  
In contrast, disturbed flow, with low and reciprocating WSS, induces selective 
expression of atherogenic and thrombogenic genes (pro-oxidant, proinflammatory, 
procoagulant, and proapoptotic) in endothelial cells [108]. Dai et al. compared the effects of 
two different atheroprone and atheroprotective shear stress patterns in vitro and demonstrated 
an important effect of low and oscillating WSS on the EC cytoskeleton, interleukin 
production, and nuclear translocation of transcription factor NF-κB to enhance expression of 
adhesion molecules [109]. Disturbed flow promotes an inflammatory and thrombotic 
phenotype in arterial ECs, increasing binding of monocyte chemotactic protein-1 (MCP-1) to 
the cysteine-cysteine receptor and stimulating SMC migration and proliferation, all of which 
may enhance NIH [110, 111]. 
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Using pulsatile computational fluid dynamics simulation with idealized models of AVF, 
Ene-Iordache et al found that despite the high flow rate after AVF creation, WSS in the areas 
of the juxta-anastomotic vein was low and oscillating, both in end-to-side and end-to-end 
anastomosis configurations [39]. Due to the pulsatility of flow during the cardiac cycle, 
recirculation and reattachment flow with low velocity develops near the wall, inducing 
disturbed flow with low and reciprocating WSS on the inner surface of the juxta-anastomotic 
segment and on the distal artery. In a parametric idealized model of end-to-side AVF, 
Ene-Iordache et al further studied whether the anastomosis angle influences the pattern of 
disturbed flow. Quantification of these areas showed that the smaller the angle, the smaller 
the area of low and oscillating WSS, as quantified by the relative residence time. These 
results suggest that an acute anastomosis angle (30º) should be preferred to minimize the risk 
of NIH in the juxta-anastomotic vein [112]. They also demonstrated that in hemodialysis 
patients, the peak shear stress rather than the average shear stress, is the key factor in driving 
vessel dilatation to increase blood volume flow [113]. 
Bharat et al. performed a clinical study in patients undergoing radiocephalic AVF 
comparing three different anastomotic techniques. A novel technique of vascular anastomosis, 
the piggyback straight-line onlay technique, was characterized by a very small anastomosis 
angle and resulted in very few juxta-anastomotic stenoses compared to the traditional 
end-to-side and side-to-side techniques [114]. By using the piggyback straight-line onlay 
technique, disturbed flow is reduced due to the acute angle and the venous wall injury 
produced by the traditional torsion of the juxta-anastomotic vein is minimized [114]. 
Recently, Sadaghianloo et al reported that radial-cephalic fistulae with angles <30 º have 
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reduced primary and secondary patency and increased numbers of interventions, suggesting 
that, if possible, surgeons should avoid an anastomotic angle of <30 º when creating 
radial-cephalic fistulae [115]. Chemla et al reported that AVF created with the VasQ™, an 
external support device, showed a high unassisted maturation and patency rate, possibly by 
minimizing flow disturbance around the area of anastomosis [116]. All of these data suggest 
that research based on anastomotic geometry may optimize the flow state and potentially be 
used for preoperative surgical planning. 
Responses to injury 
Endothelial and vascular injury results in the activation, proliferation and migration of 
fibroblasts, smooth muscle cells, and myofibroblasts from the media and/or adventitia to the 
intima; complex interactions of adhesion molecules, inflammatory mediators and chemokines 
results in venous NIH [117]. During this process, inflammation, oxidative stress, cellular 
phenotype change and migration of vascular cells and ECM remodeling play important roles.  
 
Inflammation  
In the inflammatory state of the uremic environment, the injury of AVF creation and 
local hypoxia is characterized by the presence of CD68-positive macrophages and 
CD3-positive lymphocytes. This infiltration is more significant in the setting of CKD [118]. 
Some inflammatory cytokines are upregulated such as IL-6, IL-8, MCP-1, and PAI-1 [61, 63, 
119], and these mediators are associated with fistula failure [120]. IL-6 and TNF-α are more 
highly expressed in thrombosed AVF, and both CRP and fibrinogen are associated with AVF 
failure [121, 122].  
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CD68- and CD3- positive cells have been found in increased numbers in stenotic vessels. 
Macrophage migration inhibitory factor (MMIF) is hypothesized to play an important role in 
this local inflammatory response, potentiating neointimal thickening by driving inflammatory 
cells toward the neointima and leading to the proliferation of medial and intimal cells [123, 
124]. MMIF has been identified in clinical and experimental models of vascular access. 
MMIF acts through the CD74 receptor, chemokine receptor 2, and chemokine receptor 4 
[123]. These in turn act through extracellular signal-regulated and p38 mitogen-activated 
protein kinase pathways that up-regulate vascular endothelial growth factor (VEGF)-A, 
interleukin (IL)-8, and monocyte chemotactic protein-1 (MCP-1) [124].  
MCP-1 is a potent chemokine that plays an important role in atherosclerosis and other 
vascular diseases through promoting chemotaxis of monocytes and macrophages, activation 
and migration of endothelial cells, proliferation and migration of smooth muscle cells, and 
induction of procoagulant mediators [125-128].  Expression of MCP-1 increased 1 week 
after AVF creation in mice, and was localized within the endothelium, smooth muscle cells, 
and leukocytes in a rodent AVF model. The MCP-1 knockout mouse model showed reduced 
NIH [129]. Moreover, in the murine model of CKD with AVF, there is an increase in gene 
expression of arginase-1, a marker for proinflammatory macrophages, followed by an 
increase in inducible nitric oxide, a marker for reparative macrophages [130].  Thus, MCP-1 
appears to be upregulated very early after AVF creation and serves as a mediator for AVF 
dysfunction and failure. 
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Oxidative stress 
Patients with ESRD have systemic inflammation and oxidative stress; the hemodynamic 
changes and local injury of the AVF procedure may further increase oxidative stress in the 
AVF wall.  Oxidative stress and injury stimulates synthesis and secretion of ROS that in 
turn stimulate numerous signaling pathways, regulating diverse processes such as smooth 
muscle cell migration and proliferation as well as activating latent MMP, potentially 
mediating many aspects of venous remodeling [64, 131]. For example, superoxide can 
deplete NO, resulting in disruption of numerous pathways with resultant endothelial cell and 
general vascular dysfunction. 
Recent investigations have shown that heme oxygenase (HO) production is related to 
AVF function [132-136].  HO is a cytoprotective and rate-limiting enzyme responsible for 
heme degradation, generating free iron, biliverdin, and carbon monoxide; biliverdin is 
subsequently converted to bilirubin by biliverdin reductase, and free iron is rapidly 
sequestered by ferritin [134]. Bilirubin is a free radical scavenger that blocks lipid 
peroxidation [137]. Carbon monoxide is a physiologically important vasodilator, 
acting via cyclic guanosine monophosphate (cGMP) [138]. HO exerts antioxidant, 
anti-inflammatory, antiapoptotic, and angiogenic functions through its reactive products [134, 
137, 138]. HO-1 is the inducible isoform, whereas HO-2 is expressed constitutively.  
Patients with HO-1 gene polymorphisms characterized by long GT repeats, resulting in less 
HO-1 production, were more likely to have worse AVF patency [132, 133]. In murine AVF, 
HO-1 gene expression is markedly induced in the vascular smooth muscle cells; HO-1 
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knockout mice how reduced patency with thinner vein walls and increased luminal area, as 
well as increased expression of proinflammatory and pro-oxidant mediators such as MCP-1, 
MMP-2 and MMP-9 [139].  A functional AVF also requires HO-2 [135]. Shear stress can 
regulate HO-1 activity, with high flow inducing HO-1 to generate NO and 
mitochondria-derived hydrogen peroxide; low flow induces lower levels of HO-1 that lead to 
macrophage infiltration and superoxide production within the vessel wall, suggesting an 
important role for HO in promoting outward remodeling and preventing NIH [140]. 
 
Cellular phenotype change and migration of vascular cells 
The development of NIH is a complex process that requires activation, phenotype change 
and migration of vascular cells; NIH that forms at the venous anastomosis of a dialysis access 
graft or fistula is comprised primarily of smooth muscle alpha-actin-positive, synthetic 
VSMC phenotype or vimentin-positive and desmin-negative myofibroblasts that probably 
migrated from the media or adventitia layers in response to vascular injury [52, 75]. Other 
studies have suggested that bone marrow–derived cells are capable of differentiation into 
smooth muscle cells and may be another potential origin of neointimal cells [54, 141].  
Interestingly, VSMC from the proximal artery may contribute substantially to venous intimal 
hyperplasia; in a murine AVF model increased Notch signaling can drive migration of these 
cells to the venous outflow tract [142]. 
 In addition to increased cell numbers, there is synthesis of new ECM within the intima 
to form the lesion of NIH [21, 103, 117]. VSMC also become resistant to NO, decreasing 
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SMC relaxation and preventing AVF maturation by reducing the ability to successfully 
outward remodel [143]. 
These data show that the entire vessel wall is involved in the processes that lead to access 
failure, and suggest additional targets for potential therapy; recent studies have demonstrated 
the potential to target and treat the adventitial space to prevent the adventitial response to 
injury and prevent AVF failure [56, 144, 145]. 
 
Growth Factors and Cell Adhesion Molecules 
Numerous growth factors and cytokines play roles during AVF maturation, particularly 
by regulating pathways that control ECM synthesis, secretion, and degradation, as well as 
through control of cell proliferation and migration [42].  
Local inflammation with monocyte infiltration into the AVF increases expression of 
TGF-β1 and insulin-like growth factor-1 (IGF-1) [74]. TGF-β1, despite its classically having 
anti-inflammatory properties, leads to ECM deposition, potentially causing thrombosis [74]. 
Differences in TGF-β1 polymorphisms, result in differing levels of TGF-β1 production, have 
been correlated with AVF patency [71]. TGF-β is expressed within stenotic AVF, and 
correlates with areas of ECM deposition; TGF-β1 also activates the fibroblast transition to the 
myofibroblast phenotype [146]; myofibroblasts are the major cellular component found in 
AVF stenoses, producing ECM proteins and MMP [52].  Sustained TGF-β expression 
abolishes myofibroblast disappearance and leads to NIH [63]. In toto, increased expression of 
TGF-β is associated with decreased AVF patency, likely due to increased deposition of ECM 
[73, 74].  
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Other growth factors participate in AVF maturation. IGF-1 also induces ECM synthesis, 
smooth muscle proliferation and migration, and inhibits apoptosis [74]. Platelet-derived 
growth factor (PDGF) and basic fibroblast growth factor (bFGF) also play significant roles in 
stimulating cell proliferation and migration. Both PDGF-α/β and IGF-1 expression are 
upregulated in AVF [61, 64].  Vascular endothelial growth factor (VEGF) plays several 
roles in vascular remodeling, including stimulation of endothelial proliferation and 
differentiation, modulation of smooth muscle cell proliferation and migration, angiogenesis, 
ECM deposition, and modulation of the inflammatory response. VEGF may also play an 
inhibitory role in AVF adaptation, since overexpression of VEGF-A contributes to negative 
remodeling and NIH, whereas inhibition of VEGF-A is associated with increased lumen area 
and decreased inward remodeling [56].  
Selectins facilitate leukocyte adhesion. P-selectin is present on endothelial cells and 
platelets, and E-selectin is present on endothelial cells; ICAM and VCAM facilitate 
additional binding and migration [147]. P-selectin and E-selectin expression are both 
upregulated early after AVF creation, followed by decreased P-selectin expression after 1 
month [61]. VCAM-1, but not ICAM-1, is highly expressed in thrombosed and stenotic AVF 
[121]. β-catenin and c-Myc expression are increased 1 week after AVF creation, correlating 
with decreased N-cadherin and associated with smooth muscle cell proliferation [148]. 
 
ECM remodeling  
ECM remodeling involves coordinated synthesis, secretion, and degradation of ECM, 
which plays an important role both in normal AVF maturation as well as in the development 
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of neointima and AVF failure [20, 21, 149]. ECM degradation occurs early after AVF 
creation, coincident with early increased expression of MMP and TIMP-1 [70]. Outward 
remodeling in response to the increased arterial flow requires early expression of MMP-2 and 
MMP-9 to degrade cell basement membranes and the internal elastic lamina, allowing vessel 
enlargement [150]. A high serum ratio of MMP-2 to TIMP predicts AVF maturation [65, 66, 
68]. Other elastases such as cathepsin S and cathepsin K are also upregulated in the AVF and 
may be associated with degradation of the internal elastic lamina [66].  Diminished 
elastin results in enhanced outward remodeling, suggesting that elastin degradation might be 
an option to improve AVF maturation [151]. 
However, the disruption of the elastic lamina and loss of integrity of this structural 
barrier may allow migration of medial VSMC or adventitial fibroblasts into the intima. 
Moreover, elastin degradation products can act as chemo-attractants for VSMC. MMP-2 and 
MMP-9 are also elevated in AVF stenoses and may play a role in thrombosis. Decreased 
expression of MMP-1, MMP-3, and MMP-9 have been linked to increased AVF failure and 
stenosis secondary to accumulation of ECM and impaired wall remodeling [152]. Although 
the role of TIMP is not clear [65-67], an unbalance of MMP and TIMP may contribute to the 
failure of AVF maturation.  ADAMTS-1 is a matrix metalloproteinase that is expressed 
during AVF maturation and plays a role similar to MMP-2 and MMP-9; reducing ADAMTS1 
expression leads to positive vascular remodeling [144]. 
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3. Late failure in the mature AVF 
Although a mature AVF can support HD, in the setting of uremia and other systemic 
abnormalities, compounded with local injury due to the anastomotic configuration as well as 
repeated needle puncture, even the mature AVF is predisposed to eventual failure.  NIH 
worsens with time, typically leading to stenosis of the AVF venous limb. This later failure 
usually requires interventional treatment or surgical revision to maintain the access for 
functional HD. 
 
3.1 Systemic abnormalities 
ESRD patients have systemic abnormalities, such as uremia, systemic inflammation, 
endothelial dysfunction, lipid abnormalities, hyperparathyroidism, hyperphosphatemia and 
hypercalcemia [21, 153-155]. These abnormalities may predispose the vessel wall to inward 
remodeling and stenoses after AVF creation. 
Uremia 
The inherent uremia of ESRD increases inflammation and oxidative stress [154, 155]. 
This oxidative stress is further increased by HD, which causes activation of phagocytes, 
release of oxygen radicals, peroxidation of lipids and ultimately depletion of the patient’s 
antioxidant protectants [154, 156]. Certain cytokines implicated in the formation of NIH, 
such as IL-6, TGF-β and TNF-α, are elevated in uremia [120]. Uremia adversely affects 
endothelial function resulting in a prothrombotic state, increasing the tendency for calcific 
uremic arteriopathy (CUA)
 
[88, 157]. CUA is associated with multiple histologic 
abnormalities that collectively result in medial calcification, stenoses, fibrosis, 
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proinflammatory and prothrombogenic arterioles that are compatible with a calcific 
obliterative vasculopathy. The mechanism is thought to be initiated by the interaction of 
uremic hyperphosphatemia, multiple uremic toxins, and reactive oxygen species (ROS) with 
decreased local vascular calcification inhibitory proteins such as Matrix Gla protein (MGP) 
and the systemic globulin: fetuin-A—(a2-Heremans-Schmid glycoprotein) AHSG [158]. 
 
Systemic inflammation 
Inflammation is a typical prominent feature of ESRD and contributes to the uremic 
phenotype in advanced stages of CKD [155]. Systemic concentrations of both pro- and 
anti-inflammatory cytokines are often several fold higher than in healthy individuals
.
[159, 
160]. Persistent inflammation is also a major cause of vascular aging and vascular 
calcification [159, 161]. 
 
Endothelial cell dysfunction 
Due to the negative impacts of uremia and oxidative stress on the endothelial cells, 
flow-mediated, endothelium-dependent vasodilation is markedly reduced in uremic patients 
compared with normal control patients [162, 163]. The reasons for this endothelial 
dysfunction include increased oxidative stress, the presence of NO inhibitors such as 
asymmetric dimethylargine (AMDA) and a reduced number and function of endothelial 
progenitor cells [164]. AMDA accumulates with progressive CKD, and high levels are 
associated with aggressive restenosis after angioplasty [165].  AMDA and glycation end 
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products (AGE) lead to decreased NO bioavailability, impairing arterial dilation as well as 
impairing NO-related signaling [166]. 
 
Other abnormalities 
Dyslipidemia is a well-established traditional risk factor for atherosclerosis in the general 
population in addition to patients with CKD and may actively participate in the increased 
cardiovascular morbidity [153]. Hyperphosphatemia and hypercalcemia, typical features of 
advanced CKD, are often accompanied by dysregulation of parathyroid hormone (PTH), 
contributing to the inflammatory state [167]. They also induce vascular calcification and 
stiffness [161].  
3.2 Pre-existent vascular pathology 
The role of pre-existent arterial and venous vasculopathy in uremic patients has been 
gathering increased attention. Vessel morphology and function seen with preoperative duplex 
ultrasound mapping correlate with AVF maturation and patency [168]. The systemic 
abnormalities in ESRD patients induce accelerated atherosclerosis, vessel thickening, 
vascular calcification and stiffness [166, 169]. Whereas atherosclerosis is associated with 
intimal calcification, calcification of the media occurs independently of atherosclerotic 
plaque formation and is commonly observed in all-diameter arteries in CKD patients [170]. 
This arterial vasculopathy impairs the vessels ability to expand upon exposure to high-flow.  
The detrimental effects of CKD on the arterial system may affect veins in a similar 
manner [171]. Marked pre-existing segmental venous disease is frequently present in patients 
with ESRD prior to vascular access surgery [172, 173].  Lee et al. reported extensive 
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calcification in the intima and media of venous segments that were harvested at the time of 
vascular access surgery [173].  Venous calcification is likely to reduce venous compliance, 
as it does in arteries, potentially limiting the ability of the vein to dilate and outward remodel 
for successful AVF maturation. 
Although minimum vein diameter (MVD) has been reported as a unique clinical factor 
associated with both AVF maturation and long-term patency [174], other studies suggest that 
forearm venous distensibility is a better predictor of successful AVF maturation [175], which 
is consistent with the increased outward remodeling of the venous AVF limb compared with 
the feeding artery [37]. Additional studies are needed to determine the impact of pre-existing 
venous calcification on AVF maturation failure and whether this is a potentially modifiable 
factor for clinical treatment [168]. 
 
 
Future Approaches to Treatment 
With only 26-58% of arteriovenous fistulae functional at 1 year various therapies have 
been pursued to treat access failure and improve long-term patency.  Many medical 
treatments using different drugs aimed at decreasing access failure and improving patency 
have been examined in patients using an AVF or AVG for HD.  A recent systematic review 
and meta-analysis reported the effects of aspirin, ticlopidine, dipyridamole, dipyridamole plus 
aspirin, warfarin, fish oil, clopidogrel, and sulfinpyrazone. The study showed that three trials 
compared the platelet aggregation inhibitor ticlopidine versus placebo and favored active 
treatment (OR 0.45, 95% CI 0.25 to 0.82; p = 0.009); three RCT assessed aspirin versus 
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placebo and did not show a statistical benefit (OR 0.40, 95% CI 0.07-2.25; p = 0.30); two 
trials compared clopidogrel with placebo and did not favor treatment (OR 0.40, 95% CI 0.13 
to 1.19; p = 0.10); two RCT assessed fish oil and did not favor treatment (OR 0.24, 95% CI 
0.03-1.95; p = 0.18); and single trials comparing dipyridamole alone, dipyridamole plus 
aspirin, and sulfinpyrazone against placebo favored active treatment but a meta-analysis 
could not be undertaken; a single trial of warfarin versus placebo found warfarin resulted in 
increased bleeding complications and worse patency rates [176].  Despite the overall quality 
of evidence being low with short follow-up, this systematic review showed that there 
currently is no adjuvant treatment showing increased AVF or graft long term patency [176]. 
Table 2 summarizes the most popular current approaches to treatment of the failing AVF, 
as well as some treatments that may become more popular in the future.  Despite surgical 
revision having traditionally been the most effective treatment of local disease, the current 
standard treatment for arteriovenous stenosis is percutaneous transluminal angioplasty (PTA) 
[177] [12].  Although PTA can improve patency and function in some cases of thrombosis 
and stenosis, PTA is not the optimal treatment for many lesions including resistant or 
recurrent stenosis [178].  This section of the review focuses on treatment of AVF access 
failures, broadly dividing them into stimulatory and inhibitory treatments, with further 
division into endovascular approaches, perivascular approaches and internal/external support 
devices.  
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Stimulatory Treatments 
Stimulatory treatments recapitulate AVF maturation by promoting dilation and/or wall 
thickening, encouraging the cells of the intima, media or adventitia to proliferate or 
differentiate into useful phenotypes that will allow the fistula to mature or become usable 
after stenosis or occlusion. The two commonly used stimulatory endovascular approaches are 
currently balloon-assisted maturation (BAM) and angioplasty with stent placement. Cutting 
balloon angioplasty remains popular as well. 
 
Balloon Assisted Maturation 
The BAM technique uses repeated balloon angioplasty to disrupt the venous wall and 
sequentially dilate the vein to a larger diameter useable fistula; with this technique, it is 
possible to use even smaller diameter veins for access [179, 180].  However, the concern 
with this technique lies in its very nature; angioplasty injures the intima and media to produce 
NIH [181].  Although balloon injury has been described most commonly in the context of 
arteries, it is likely that veins show a similar response to angioplasty, especially in the uremic 
environment of renal failure. Diabetes, the most common etiology for renal failure, is also 
implicated in endothelial dysfunction. The clinical question is how to modulate the NIH 
response to allow this technique to achieve long term durability and successful use of the 
access site. 
Although there is a relative paucity of randomized data on this technique, there are 
several positive short term studies. One report of 53 patients showed 85% secondary patency 
at 1 year; complications did include occlusion, conversion to a graft, and ligation due to steal 
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[179].  Another report of 42 fistulae with maturation failure treated with 1.45 ± 0.57 balloon 
angioplasties showed a success rate of 46.2% at 1 year; however, there was no significant 
difference in AVF flow ratio between the successful and failure groups [182]. Miller et al 
matured 118 out of 122 fistulae requiring 1.5 interventions per access year with a secondary 
patency of 75% at 1 year; however 14 patients with upper arm fistulae required stents in the 
cephalic arch to maintain patency [183]. Gallagher et al performed 185 BAM in 45 patients 
(mean 3.7 procedures per patient); all cases except one were successfully dilated but 7 
patients failed to mature due to cephalic arch and subclavian vein stenosis, with maturation 
after angioplasty of the venous outflow [184]. 
Interestingly, BAM is frequently complicated by vessel rupture but rupture does not 
necessarily cause fistula failure. Derderian et al performed 139 BAM in 30 patients with 74 
hematomas post procedure but still noted a statistically significant increase in flow [185].  
Although BAM has appeal and early reports suggest that it might be a useful procedure, as 
yet no blinded randomized clinical trial exists to allow for conclusions on its clinical use. 
 
Cutting Balloon Angioplasty 
Cutting balloon angioplasty is used to dilate stenoses, and like BAM, creates trauma to 
the vessel wall, but attempts to limit the trauma; longitudinal incisions along the stenosis are 
made in a controlled fashion, at lower pressures than the conventional balloon, potentially 
also reducing risk of vessel rupture. 3 or 4 blades are mounted longitudinally on a 
non-compliant balloon that after inflation create incisions and release hoop pressure; the 
lower pressure and decreased force is thought to reduce the risk of a neoproliferative response 
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and restenosis [186], and may limit dissection [187]. Several studies have reported improved 
patency at up to 6 months [188-192]. Prospective randomized trials have had heterogeneous 
data but not conclusively shown long term durability [193-195]. 
 
Stenting 
Angioplasty with stenting of failing fistulae is another tool to treat resistant stenoses; 
multiple studies have reported higher primary and secondary patency rates after stent 
placement, in both fistulae and grafts.  One prospective multicenter randomized trial tested 
self-expanding nitinol stents covered with PTFE and showed a higher 6-month patency rate 
in the stent graft group compared to balloon angioplasty alone (51% vs. 23%, p<0.001); there 
was also greater freedom from subsequent interventions (32% vs. 16%, p=0.03) and less 
restenosis (28% vs. 78%, p<0.001) [196].  A meta-analysis of 10 studies suggested there 
was improved primary patency at 6 months in those treated with nitinol stents compared to 
angioplasty; however, bare metal stents showed no significant increase in patency [197].  
Covered stents can also be used to treat pseudoaneurysms that develop within the access 
[198].  Other issues with stents include how to locate sites for needle cannulation of the 
access in relationship to the stent, as well as the potential for infection of the foreign body. 
 
Elastase Therapy 
Elastin within the vessel wall provides elastic recoil and resting vessel tone. In animal 
AVF models, delivery of recombinant human type 1 pancreatic elastase resulted in vessel 
dilation, inhibition of NIH and improved patency [199]. These findings suggest that use of 
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elastase in humans could improve AVF dilation and maturation; elastase must be delivered 
topically over the fistula adventitia as elastase is inactivated in blood. 
A randomized, double blinded, placebo controlled dose escalation study suggested 
improved primary patency at low doses [200]. A second double-blinded, randomized, placebo 
controlled trial suggested improved unassisted maturation but without increased primary 
patency [201, 202].  Without meeting the primary efficacy end point, it is not clear whether 
additional trials will be performed. 
 
Inhibitory Treatments 
Inhibitory treatments seek to inhibit NIH. Treatments can be applied primarily to prevent 
initial access failure and possibly promote maturation, or treatments can be applied 
secondarily, to directly treat a failed AVF or to prevent secondary restenosis associated with a 
stimulatory treatment such as angioplasty.  Several delivery strategies can be used including 
direct delivery to the endothelium, delivery to the adventitia, or delivery to the entire vessel 
wall; mechanical support devices have also been used. 
 
Drug Eluting Angioplasty 
Drug eluting angioplasty has shown encouraging results in the management of coronary 
artery in-stent restenosis and peripheral arterial stenosis; as such there has been recent interest 
to use this technique to treat failing AVF, with paclitaxel being the most commonly reported 
drug.  Katsanos et al treated 20 patients with failing arteriovenous fistula with paclitaxel 
coated balloon angioplasty; there was an overall statistically significant improvement in 
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primary patency at 6 months (70% vs 25%); however only 35% had autologous fistulae and 
in these cases there was a 45% device success rate with patients requiring high-pressure post 
procedure dilatation [203].  Lai et al treated radiocephalic fistulae with either plain balloon 
angioplasty or plain balloon angioplasty followed by paclitaxel-coated balloon; there was 
increased 6-month patency in the paclitaxel group, but not at 12 months [204].  Kitrou et al 
showed a numerical improvement with paclitaxel coated balloon angioplasty compared to 
plain angioplasty but there was no statistical significance in outcome; however, there were 
only 7 patients in each group [205]. A meta-analysis of 6 studies, 2 RCT and 4 cohort studies, 
reported encouraging 6-month patency with drug eluting balloon angioplasty (70-97% vs. 
0-26%), although in these studies the numbers of patients were small and heterogeneous 
[206]. Infection also remains a concern for paxlitaxel [207]. 
Dual antiplatelet therapy (DAPT) is beneficial and currently recommended for patients 
with coronary stenosis after placement of a DES [208], and also beneficial for patients with 
peripheral arterial diseases to reduce major adverse cardiovascular events and death [209], 
although a recent meta-analysis reported lack of evidence for DAPT after endovascular 
arterial procedures [210]. Although some studies used DAPT or clopidogrel after 
implantation a DES to treat AVF stenosis [203, 211], there is no study of DAPT on the 
outcome of AVF patency after DES treatment. 
 
Cryoplasty 
Cryoplasty uses liquid nitrous oxide to fill the balloon during inflation, cooling the vessel 
wall to -10 degrees Celsius, with the goal of inducing smooth muscle cell apoptosis.  
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Subzero temperatures induce ice crystal nucleation in the vessel wall extracellular fluid to 
produce a hypertonic environment, since ice does not incorporate solutes, resulting in osmotic 
dehydration; upon removal of the cold source, the extracellular fluid thaws and osmolality 
returns to normal resulting in rehydration of the smooth muscle cells and induction of 
apoptosis. Cell survival is dependent on the rate of freezing and thawing cycles, the lowest 
temperature reached and the length of time at subzero temperature. 
In porcine PTFE grafts there was no significant difference in intimal hyperplasia but a 
significant difference in media to intima thickness ratio at 4 weeks [212]. Rifkin et al treated 
5 patients with perianastamotic PTFE graft-vein stenoses after 3 failed balloon angioplasty; 3 
patients had no recurrence of stenosis at 12 weeks [213]. Gray et al treated 20 patients (AVG 
18 patients; AVF 2 patients), with 80% needing immediate post cryotherapy angioplasty to 
achieve anatomical success; 3-month patency rates were equivocal at 3 months but only 16 
and 25% at 6 months. Cryotherapy was also more painful than angioplasty [214]. 
Brachytherapy 
Endovascular brachytherapy delivers beta radiation to the vessel wall, typically using 
either high doses over a short period of time or low doses over a long period using 
beta-particle emitting stents. Brachytherapy decreases vascular smooth muscle cell 
proliferation and migration [215]. 
In a canine PTFE graft model, brachytherapy was associated with reduced NIH at up to 9 
months [216]. An early study treating 5 patients with restenosis showed only 2 patients with a 
clinically patent fistula at 6 months [217].  Waksman et al treated 18 grafts with restenosis 
with 11 sites remaining patent at 44 weeks [218]. The BRAVO 2 trial aimed to randomize 
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patients into brachytherapy or sham treatment after the promising results of the BRAVO pilot, 
but this trial was halted preliminarily [219, 220]. 
 
Adventitial Wraps 
The role of adventitial wraps to deliver sirolimus or paclitaxel has been extensively 
investigated; rat, pig, dog and sheep models using paclitaxel wraps showed decreased NIH 
[207, 221-224]. A significant concern with perivascular delivery however, is leak of the 
impregnated drug to surrounding tissues; a clinical trial was stopped early due to a 25% 
increase in infections [207]. This trial, however, used mesh for delivery to PTFE grafts. 
Sanders et al used a non-porous polymer barrier laminated with a drug loaded hydrogel 
to allow unidirectional release towards the target area. In a porcine model there was no 
detection of the drug within any surrounding tissues; addition of a polylactide-co-glycolide 
wrap showed acceptable degradation over time and was undetectable by day 35 [224]. 
An interesting study described a sirolimus-eluting collagen membrane (Coll-R). In a 
small clinical trial of 12 patients, there was minimal toxicity and primary patency rates were 
76% and 38% at 12 and 24 months respectively [225]. A phase 3 trial is currently in progress. 
 
Mechanical Support Devices 
Mechanical support devices can be used to optimize the geometry of the fistula 
anastomosis to prevent or delay NIH. The Optiflow
TM 
device has been the most studied; in a 
human pilot study safety and technical success were achieved in 10 patients [226]. A follow 
up study of 41 patients showed unassisted patency of 78% at 90 days with no device related 
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adverse events [227]. Similarly, the VasQ
TM
 device provides an external support to control the 
geometry and flow, with a small study reporting maturation rates of 74% at 6 months [116]. 
 
Gene Therapy 
Gene therapy continues to be of interest, with research directed towards understanding 
what patient risk factors predispose to access failure and thus might be suitable for 
appropriate targeted gene therapy. Several polymorphisms have been associated with vascular 
access thrombosis including methylenetetrahydrofolate (MTHFR), HO-1, factor V, TGFβ-1 
and klotho (KL) [71, 133, 177, 228-230].  Polymorphisms of NOS have also been 
implicated in arterial restenosis [231].  Single nucleotide polymorphisms in the gene for 
Factor V were significantly associated with increased risk of access failure despite treatment 
with antiplatelet agents [232]. 
Gene therapy can alter luminal area and stenosis in large animal PTFE graft models. 
Rotmans et al used C-Natriuretic Peptide to increase lumen area and the intima/media ratio 
[233]. Luo et al. showed reduced NIH with beta-adrenergic receptor kinase C-terminus [234]. 
Gene therapy targeting VEGF-A may be promising. VEGF-A is necessary at low 
concentrations to promote endothelial cell health, nitric oxide and prostacyclin production, 
vasodilatation, antithrombosis and suppression of smooth muscle cell proliferation; at high 
concentrations VEGF-A promotes angiogenesis and vasculogenesis. Systemic VEGF receptor 
gene transfer in rats decreased carotid artery restenosis, suggesting the utility of targeting this 
pathway [235]. Increased VEGF expression is associated with early AVF thrombosis in 
human patients [236], and patients with the VEGF-936C/C gene polymorphism have a 5.54 
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increased risk of fistula thrombosis [237]. Lentivirus inhibiting adventitial VEGF-A 
expression decreased cellular proliferation and constrictive remodeling and increased patency 
in a mouse model [56]. However, a human trial administering VEGF-D was stopped early 
due to poor recruitment[238]. 
 
Future Directions 
Successful hemodialysis requires a strong collagen tube that can be punctured 
repetitively to support the high flows necessary for efficient dialysis exchange. Veins are 
typically preferred, as arterial use can lead to ischemia and prosthetics have reduced patency 
and increased infection.  However, the thin walled veins must successfully adapt to the 
arterial environment with a combination of diameter expansion and wall thickening.  Failure 
to mature successfully is an important mechanism of access failure, just as NIH is an 
important mechanism of late failure. Accordingly, therapy to promote maturation, e.g. 
diameter expansion and wall thickening, is an important component of providing successful 
access; however, promoting wall thickening for strength, without exuberant thickening and 
NIH, is a current challenge. 
The role of hemodynamics such as shear stress in the development of NIH is recognized, 
especially in the pathogenesis of juxta-anastomotic stenosis that frequently develops along 
the inner wall of the swing segment. Both pharmacological as well as mechanical approaches 
may be applicable for therapy. The new RADAR technique to create AVF, e.g. minimizing 
venous handling and potential for wall ischemia, alters hemodynamics and may be a simple 
and low-cost method to improve access patency [239]. 
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An interesting alternative that may obviate fistulae is the use of tissue engineered blood 
vessels.  Although still in development and trials, tissue engineered grafts can resist high 
pressures, providing an endothelial-lined tube that supports dialysis [240, 241]. Continued 
advances in tissue engineering and 3D printing may show that tissue engineered vessels 
might replace the current gold standard fistula.  
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Figure Legends 
 
Figure 1. Schematic representation of the venous wall structural changes that occur after 
AVF creation. AVF successful maturation integrates wall thickening and outward remodeling. 
A failed AVF can be due to early failure to mature, with failure to develop outward 
remodeling or wall thickening, or may be due to later development of neointimal hyperplasia 
and impaired outward remodeling in a previously functional conduit. 
 
Figure 2. Diagram depicting the 3 phases of ECM changes during the adaptive process of 
AVF maturation. There is an early phase of ECM breakdown from MMP degradation. A 
transition phase follows with collagen and elastin reorganization of the venous scaffold. A 
later rebuilding phase strengthens the matrix of the AVF with larger non-collagenous and 
glycoproteins. TIMP-1, osteopontin and thrombospondin-2 (TSP-2) are highly expressed 
throughout AVF maturation suggesting regulatory roles for these proteins. 
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Table 1.  Types of AVF failure. 
 
AVF failure type Time Definition Pathophysiology 
Early thrombosis < 3 weeks thrombosis of the access Hypercoaguability 
Failure to mature < 6 months Patent access but not suitable 
for cannulation or high 
efficiency hemodialysis 
Inability to remodel 
outwardly 
Late failure > 3 months a mature AVF used for at 
least 3 months that 
subsequently develops a 
problem requiring 
intervention 
Neointimal 
hyperplasia 
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Table 2. Current and future approaches to treatment of the failing AVF. 
 
Gold Standard: percutaneous transluminal angioplasty (PTA) or surgical revision 
Stimulatory Approaches: promote dilation and/or wall thickening 
 Application  Limitation 
Balloon Assisted 
Maturation 
Promotes maturation in an AVF with 
limited outward remodeling 
Injures intima and media, 
increasing likelihood of NIH and 
recurrent stenosis; vessel rupture 
Cutting Balloon 
Angioplasty 
Dilate stenoses with reduced wall 
trauma 
Some wall trauma; long term 
durability 
Angioplasty with Stent Dilate stenoses Optimal stent type and design not 
established; long term durability 
Elastase Therapy Facilitate vessel dilation Dose and efficacy not established; 
requires topical delivery 
Inhibitory Approaches: prevent or inhibit NIH 
Drug Eluting 
Angioplasty 
Inhibit VSMC proliferation Optimal drug and dose not 
established; single treatment 
Cryoplasty Induce VSMC apoptosis Variability in cell survival after 
freeze-thaw; more painful than 
angioplasty 
Brachytherapy Inhibit VSMC proliferation and 
migration 
Dose and efficacy not established 
Adventitial Wraps Inhibit VSMC proliferation Wrap design and toxicity; optimal 
drug and dose not established 
Mechanical Support 
Devices 
Optimize AVF geometry Limited data 
Gene Therapy Identifiable patient risk factors Optimal targets not established; 
ethical considerations for human 
trials 
 
PTA, percutaneous transluminal angioplasty; AVF, arteriovenous fistula; BAM, balloon assisted maturation; NIH, 
neointimal hyperplasia; VSMC, vascular smooth muscle cell 
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